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Nef is an important pathogenesis factor of HIV-1 with a multitude of effector functions. We have designed a broad panel of isogenic viruses
encoding defined mutants of HIV-1SF2 Nef and analyzed their biological activity in the context of productive HIV-1 infection. Analysis of
subcellular localization, virion incorporation, downregulation of cell surface CD4 and MHC-I, enhancement of virion infectivity and facilitation of
HIV replication in primary human T lymphocytes mostly confirmed the mapping of Nef determinants previously reported upon isolated
expression of Nef. However, reduced activity in downregulation of CD4, infectivity enhancement and virion incorporation of a Nef variant (Δ12–
39) lacking an amphipatic helix required for binding of a cellular kinase complex and the association of Nef with MHC-I/AP-1 suggested a novel
role of this N-terminal motif. The SH3 binding motif of Nef was partially required for infectivity enhancement and replication but not for receptor
downmodulation. In contrast to previous results obtained using other Nef alleles, non-myristoylated SF2-Nef was only partly defective when
expressed during HIV infection and was present in HIV-1 particles. Importantly, incorporation of Nef into HIV-1 virions was not required for any
of the tested Nef activities. Altogether, this study provides a broad characterization and mapping of multiple Nef activities in HIV-infected cells.
The results emphasize that multiple activities govern Nef's effects on HIV replication and argue against a role of virion incorporation for Nef's
activity as pathogenicity factor.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV Nef; Mutant virus panel; Virion incorporation; Myristoylation; Cell surface receptor modulation; Infectivity; ReplicationIntroduction
The accessory gene product Nef is a critical determinant for
the pathogenesis of the primate lentiviruses HIV-1, HIV-2 and
SIV. This is illustrated by low levels of replication in vivo
achieved by viruses lacking functional nef genes that lead to no
or delayed disease progression (Deacon et al., 1995; Kestler et
al., 1991; Kirchhoff et al., 1995). Such a role for Nef as
pathogenicity factor is further substantiated by a transgenic
mouse model (Hanna et al., 1998) in which isolated expression
of Nef causes AIDS like disease. Despite intense research
efforts, the mechanisms by which Nef mediates its role as⁎ Corresponding author. Fax: +49 6221 565003.
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doi:10.1016/j.virol.2006.03.044pathogenicity factor have remained obscure. Numerous activ-
ities of the viral protein, all exerted by protein interaction with
cellular ligands, have been described (Arora et al., 2002; Geyer
et al., 2001). In vivo, these activities are thought to mediate
shielding of HIV-infected cells from the host's immune
response and to directly optimize the multiplication of the
virus. Immune evasion activities of Nef include the down-
modulation of cell surface MHC class I and II molecules as well
as the induction of apoptosis in bystander cells (Collins et al.,
1998; Schwartz et al., 1996; Stumptner-Cuvelette et al., 2001;
Xu et al., 1997, 1999). The optimization of the cellular
environment for viral replication is achieved by the activation of
signal transduction cascades leading to prolonged survival of
infected cells and increased virus production (Fackler and Baur,
2002; Schrager and Marsh, 1999; Swingler et al., 2003; Wolf et
al., 2001). Additionally, Nef triggers the downmodulation of
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the fitness of viral progeny (Garcia and Miller, 1991;
Glushakova et al., 2001; Lundquist et al., 2002). These
influences lead to enhanced infectivity of HIV particles
produced in the presence of Nef when assayed in a single
round of replication and in increased replication kinetics over
multiple rounds (Aiken and Trono, 1995; Miller et al., 1994;
Schwartz et al., 1995; Spina et al., 1994). In surgery with the
downmodulation of cell surface CCR5, removal CD4 also
interferes with superinfection of productively infected cells
(Michel et al., 2005). The individual activities of Nef appear to
be largely independent of each other, and specific protein
interaction surfaces have been mapped that mediate individual
Nef activities (reviewed in Arold and Baur, 2001; Geyer et al.,
2001). A common prerequisite to all Nef actions consists in its
tethering to intracellular and plasma membranes, which
depends on the N-terminal myristoylation of Nef. Possibly
mediated by its association with the plasma membrane, 10–100
Nef molecules are incorporated into HIV particles (Bukovsky et
al., 1997; Fackler et al., 1996; Welker et al., 1998). Whether the
virion incorporation of Nef plays a role for its effects on viral
replication remains to be defined.
While the molecular mechanisms of individual Nef activities
are being studied intensively, their relative contribution to Nef's
role as pathogenicity factor is difficult to address. Studies using
Nef mutants defective in individual protein interactions allowed
the correlation of some of its activities with enhanced virus
replication and/or disease progression. However, direct evidence
for a role of any individual Nef activity in lentiviral pathogenesis
is missing, and it seems unlikely that all activities of Nef reported
thus far will be relevant in vivo. Moreover, some of the in vitro
phenotypes of Nef are a matter of controversy, a fact that is often
attributed to the use of different alleles of the variable nef gene in
a wide array of divergent cell lines. An additional major obstacle
in revealing the pathologically relevant Nef activities consists in
the use of experimental systems that rely on the in vitro
overexpression of Nef in the absence of other HIV gene
products. While many of Nef's effects have been observed in the
context of HIV infection individually, few studies directly
compared the molecular determinants in Nef for multiple of its
biological activities in infected cells. Some of these studies
exclusively mapped the Nef determinants for optimal HIV
replication and CD4 T cell depletion (Aldrovandi et al., 1998;
Stoddart et al., 2003). Others correlated effects of Nef on HIV-1
replication with Nef activities determined in overexpression
systems of divergent cellular origin and used various Nef alleles
instead of specific isogenic mutants (Glushakova et al., 2001) or
only addressed a limited number of Nef activities in infected
cells (Lundquist et al., 2002).
Here, we generated and broadly characterized a panel of
isogenic viruses that expresses an array of established Nef
mutants. These viruses were used to analyze Nef activities in the
context of HIV infection. Our results provide evidence that CD4
downregulation correlates best with the positive effects of Nef
on HIV replication in primary human T lymphocytes and reveal
an unexpected role of an amphipatic helix in the N-terminal
anchor domain of Nef for its activities in CD4 downregulation,infectivity enhancement and boosting of HIV replication.
Furthermore, the study reveals that virion incorporation of
Nef is dispensable for its activities in infectivity enhancement
and optimization of HIV replication.
Results
Generation of an isogenic nef HIV-1 virus panel
We set out to generate a panel of isogenic HIV-1 proviral
clones encoding for 15 established Nef mutants. We chose to use
the nef gene from the HIV-1 strain SF2 since the corresponding
Nef isoform has proven very active in all assays for Nef
functions investigated thus far (Baur et al., 1994; Fackler et al.,
2001; Keppler et al., 2005; Krautkramer et al., 2004). Given that
the HIV-1SF2 virus does not replicate very efficiently due to
difficulties of Env virion incorporation (Stamatatos and Cheng-
Mayer, 1993), SF2 nef variants were introduced into the genetic
background of the HIV-1 strain NL4-3 lacking the nef gene
(Δnef ). It had been previously determined that SF2 Nef exerts
key activities of Nef such as enhancement of virion infectivity
and increase of virus replication in such a chimeric virus (Fackler
et al., 2001; Rucker et al., 2004). The prototype chimera
containing the HIV-1 NL4-3 provirus with the HIV-1 SF2 nef
gene was designated NL4-3 SF2Nef or wild type (WT), the
respective nef variants were all designated according to their
amino acid changes in the encoded Nef protein. Nef mutants
included in the panel were based on previous biochemical or
structural mapping of protein–protein interaction or modifica-
tion sites in Nef (Table 1). Two mutants were expected to impact
on Nef's ability to associate with cellular membranes, which is
thought to be vital for all of its activities. G2ANef lacks the
myristoyl receptor glycine at position 2 and can therefore no
longer be myristoylated by N-myristoyl transferase, a modifi-
cation that mediates tethering of Nef to cellular membranes
(Geyer et al., 2001; Hill and Skowronski, 2005). The R4A4
mutant lacks a cluster of basic amino acids described as
contributing to membrane targeting of Nef (Welker et al., 1998).
Another set of mutants was expected to affect Nef mediated
intracellular sorting: the LLAA and EDAA mutants no longer
recruit adaptor protein (AP) complexes or the catalytic subunit of
V-ATPase (V1H), respectively, and are deficient in CD4
internalization (Bresnahan et al., 1998; Craig et al., 1998;
Greenberg et al., 1998a, 1998b; Lu et al., 1998; Piguet et al.,
1998), while NefE4A4 is blocked in the ability to associate with
the PACS sorting adapter and does not downregulateMHC-I and
CCR5 (Greenberg et al., 1998a, 1998b; Piguet et al., 2000;
Michel et al., 2005). CD4 downregulation should also be
prevented by deleting or mutating the presumed CD4 binding
site in theΔ59–61 or W61A Nef mutants (Grzesiek et al., 1996;
Lu et al., 1998;Mangasarian et al., 1999). Another set of mutants
was designed to block individual protein interactions Nef
employs to modify intracellular signal transduction. These
include mutations that interfere with the association of Nef with
SH3 domains of e.g. Vav or Hck (P76/79A: NefAxxA, V78A,
R81A). Presumably reflecting the need for an SH3 interaction,
these mutations also abrogate the association of Nef with active
Table 1
Characteristics of Nef variants used
Nef variant Mutation Loss of interaction with Reported functional consequences
WT HIV-1 SF2 Nef – Functional Nef
G2A G2A N-myristoyl transferase Loss of membrane association, non-functional Nef
R4A4 R17/19/21/22A Membranes? Reduced membrane association
W61A W61A CD4 Defect in CD4 downregulation
E4A4 E66/67/68/69A PACS Loss of MHC-I and CCR5 downregulation
AxxA P76/79A Pak2, SH3 domains (e.g., Vav, Hck) Defect in downregulation of MHC-I and CCR5 and Pak2 association
V78A V78A Pak2, SH3 domains Defect in association with Pak2 activity
R81A R81A Pak2, SH3 domains Defect in association with Pak2 activity
L116A L116A Pak2, Nef Defect in association with Pak2 activity and Nef multimerization
LLAA L168/169A AP-1, -2, -3, V1H Defect in CD4 downregulation and infectivity enhancement
EDAA ED178/179AA AP-1, -2, -3, V1H Defect in CD4 downregulation and infectivity enhancement
E181Q E181Q c-Raf Unknown
P73A P73A TCR zeta, Pak2 Loss of FasL upregulation and association with Pak2 activity
Δ12–39 Δ12–39 NAKC Reduced Nef-phosphorylation and stimulation of Tat transactivation
Δ59–61 Δ59CAW61 CD4 Loss of CD4 downregulation
RRLL R109/110L Pak2, Nef Defect in association with Pak2 activity and Nef multimerization
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al., 1999; Saksela et al., 1995; Sawai et al., 1995). The latter
activity of Nef is also abrogated by mutations in the Pak
interaction surface of Nef, that however also interfere with the
multimerization of the viral protein (L116A, RRLL) (Liu et al.,
2000;Manninen et al., 1998; Sawai et al., 1995). In an additional
mutant (Δ12–39), an amphipatic helix was deleted that mediates
the association of Nef with a second signal transduction module,
the Nef-associated kinase complex (NAKC) (Baur et al., 1997)
as well as the association with MHC-I and AP-1 molecules
(Roeth et al., 2004). Finally, variants that have been reported to
be disrupted in their interaction with TCR zeta chain as well as
Pak2 activity (P73A) (Xu et al., 1999) or the c-Raf kinase
(E181Q) (Hodge et al., 1998) were included in the study.
Expression and subcellular localization of Nef variants
First, virus stocks were generated by transfecting proviral
DNA into 293T producer cells. Western Blot analysis of lysates
from these producer cells revealed similar Gag processing
patterns in all cases (Fig. 1A, upper panel). Transfected 293T
cells but also infected MT4 T lymphocytes produced compa-
rable amounts of p24, indicating that Nef does not impact on the
efficacy of particle production in these cells. Thus, net effects of
Nef on virus production are only observed in COS-7 cells or in
the presence of dominant-negative variants of members of the
Vav-Pak signaling cascade (Fackler et al., 1999, 2000; Lu et al.,
1996). Given this comparable virus production, the seemingly
lower levels of Gag on the left side of the membrane are most
likely due to local variations in western transfer efficiency.
Thus, Gag expression was generally comparable. Analysis of
Nef expression revealed specific gene products for all constructs
except theΔnef control (Fig. 1, lower panel). Of note, the E4A4
and Δ12–39 Nef mutants migrated faster than the other Nef
variants because of the charge changes or deletions introduced
during the creation of these specific mutants. Somewhat
reduced expression levels were observed for the E4A4,
W61A, Δ12–39, Δ59–61 and RRLL mutants of Nef. To
address the potential relevance of these variations in proteinstability for our subsequent functional analysis in T lympho-
cytes, Nef expression levels were quantified relative to Gag
expression in lysates from MT4 T lymphocytes infected with
the individual viruses (Fig. 1B). This analysis revealed that
most of the Nef variants with the notable exception of RRLL
were expressed at levels comparable or higher than wt. Such
increased expression levels were particularly pronounced for
G2A Nef. Thus, expression levels of individual Nef variants
may vary depending on the cellular environment, and for the
virus panel analyzed here, protein instability could be excluded
as a major reason for altered biological activity of individual
Nef variants in infected T lymphocytes.
The subcellular distribution of Nef is regarded a critical
parameter for its activity, but only limited information is
available on the localization of Nef and its variants in HIV-
infected cells. We therefore performed an indirect immunoflu-
orescence analysis on TZM cells 36 h post-infection after
staining of the cells with antibodies against Nef and CA (Fig. 2).
TZM cells were used to correlate Nef's subcellular localization
with its effect on infectivity enhancement (see Fig. 4). At this
time point, most of the infected TZM cells displayed large
syncytia, often containing more than 10 nuclei. Importantly, the
overall distribution of CA and Nef was not markedly different in
single cells or at earlier time points post-infection (data not
shown). The subcellular distribution of CA was comparable
independent of the virus used for infection and revealed the
expected punctate cytoplasmic distribution with some accumu-
lation at the plasma membrane. In contrast, Nef was found more
predominantly enriched in the perinuclear areas of infected
cells, with some but not all cells showing marked staining of the
plasma membrane and intracellular vesicles. No obvious
colocalization between Nef and CA was observed. When
comparing the distribution of the various Nef mutants, G2ANef,
presumably due to the loss of myristoylation, was distributed
much more diffusely in infected cells than WT Nef and was also
found within the nucleus. The E4A4 Nef variant could not be
analyzed since the stretch of acidic residues mutated in this
variant overlaps with the epitope of the monoclonal antibody
that was used for immunostaining of Nef. For all other Nef
Fig. 1. Gag and Nef expression of the virus panel. (A) Western blot analysis of lysates from 293T cells 48 h post-transfection with the indicated proviral constructs for
virus production. Numbers on top indicate the amounts of CA released in the cell culture supernatant. (B) Western blot analysis of lysates fromMT4 cells infected with
the indicated viruses. Cells were harvested and analyzed for the expression of Gag (upper panels) and Nef (lower panels). Arrows indicate unprocessed Gag (p55),
processing intermediates (p41), CA or Nef, respectively. Detection and quantification of the CA and Nef signals were carried out using the LI-COR Odyssey imaging
system and the relative Nef expression levels normalized to the respective CA signal are indicated above the lanes with wt arbitrarily set to 100%.
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changed relative to WT. This was surprising for the LLAA
and EDAA variants as mutations in the c-terminal flexible loop
of Nef are known to significantly alter its subcellular
localization when overexpressed as a CD8-Nef fusion protein
(Erdtmann et al., 2000; Janvier et al., 2003). However, such
mutations do not affect the localization of Nef in cells
transfected with Nef.GFP expression plasmids (Craig et al.,
2000; Greenberg et al., 1998a, 1998b) or HIV proviral DNA
(data not shown), indicating that this translocation is a specific
property of CD8-Nef fusion proteins. Together, these results
indicated that of all Nef variants tested in the virus panel, only
the G2A mutation has a major impact on the overall steady state
subcellular distribution of Nef. Furthermore, the presence of
other HIV gene products in infected cells does not generally
affect the localization of Nef. Subtle changes in Nef
localization, however, may be masked by secondary effects
induced by expression of the entire HIV genome in the infection
context.
Myristoylation is not required for virion incorporation of
HIV-1 SF2Nef
In a next step, we investigated the incorporation of Nef
into virus particles produced from 293T cells. Cell culture
supernatants were concentrated by ultracentrifugation througha sucrose cushion and normalized for their content of CA
(Fig. 3A; upper panel). Western blotting for the presence of
Nef revealed that significant amounts of Nef were detected in
the WT preparations (bottom panel). Virion incorporation of
Nef variants was analyzed in parallel and individual mutants
were grouped into classes with near WT incorporation (++),
intermediate (+) and undetectable incorporation (−), respec-
tively (Fig. 3A). Surprisingly, loss of virion incorporation was
only observed for the two Nef variants E4A4 and Δ12–39. In
contrast, G2ANef, which was expected to lose virion
incorporation because of the lack of N-terminal myristoyla-
tion, was detected in particle preparations at levels similar to
WTNef. Most other Nef variants displayed approximately
equal virion incorporation, while the L116R Nef mutant
reproducibly showed clearly detectable, yet somewhat re-
duced virion incorporation efficiency. To confirm the
unexpected properties of the G2A variant in virion incorpo-
ration, this analysis was repeated with two independent virus
preparations (Fig. 3B). As seen before, robust amounts of
G2ANef were detected in virus pellets from these infectious
cell culture supernatants. To exclude that the previous
mapping of Nef determinants for virion incorporation was
the consequence of high levels of expression in transfected
293T cells, we analyzed cell culture supernatants of infected
PM1 T cells (Fig. 3C). Nef and its G2A and E4A4 mutants
were expressed to comparable levels while expression of the
Fig. 2. Subcellular localization of Nef and CA in HIV-1 infected TZM cells. Immunofluorescence analysis of TZM cells infected with the indicated HIV-1 variants.
36 h post-infection cells were fixed and stained with antibodies specific for CA (left) and Nef (right). Shown are representative pictures of multinucleated syncytia, in
which the overall distribution of CA and Nef was comparable to single infected cells.
326 O.T. Fackler et al. / Virology 351 (2006) 322–339Δ12–39 Nef mutant was markedly reduced. Analysis of
virion pellets confirmed that G2ANef was incorporated in
HIV-1 virions with an efficiency comparable to that of WT,
while the E4A4 and Δ12–39 Nef variants were not detectable
in these virion preparations. The observed virion incorpora-
tion of G2ANef is in contrast to previous reports on the loss
of virion incorporation for a G2A variant of NL4-3 and HxB2
Nef proteins (Chen et al., 1998; Pandori et al., 1996; Welker
et al., 1996). Using parallel transfection of isogenic proviralclones carrying G2A variants of either SF2 or NL4-3 Nef, we
confirmed a strain specific difference where the SF2 mutant,
but not the NL4-3 mutant, was incorporated efficiently (Fig.
4A). Although we observed some variations in the efficiency
of G2A SF2Nef virion incorporation between experiments,
quantification of the data presented herein revealed that, when
normalized for the content of p24CA, G2ANef was present to
levels of 94.7 ± 18% relative to wtNef. Notably, no cleavage
of SF2 Nef by the HIV protease was detected, which had
Fig. 3. Virion incorporation of Nef variants. (A, B) Western blot analysis of virus pellets generated by ultracentrifugation of cell culture supernatants from 293T cells
that had been transfected with the respective proviral clones for virus production. Note that 5 ng or 100 ng total protein were loaded for the analysis of CA (upper panel)
or Nef (lower panel), respectively. The data shown are representative for three independent virion preparations. (C, D) Analogous analysis with virus harvested from
PM1 cells 3 days post-infection with the indicated viruses. Western blot analysis of virus pellets (C) and cell lysates (D), respectively.
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alleles (Pandori et al., 1996; Welker et al., 1996). Consis-
tently, Nef cleavage was readily detected in parallel prepara-
tions of HIV-1 NL4-3 containing NL4-3 Nef (Fig. 4A),
suggesting that the SF2Nef protein may be less susceptible to
HIV protease cleavage or the cleavage product of SF2Nef
may not be detected by our anti-Nef antibody. Since cleavage
of Nef by the HIV protease occurs within intact virus
particles and this cleavage was observed for NL4-3 Nef, these
results also argue against a contamination with microvesicles
as major source of the particle-associated Nef protein in our
preparations. This was confirmed by an additional control
where Nef was readily pelleted from supernatants of cells
expressing the HIV-1NL4-3 SF2 provirus but not a SF2Nef.
GFP fusion protein (Fig. 4B). To address whether the
differential myristoylation requirement for virion incorpora-
tion of NL4-3 and SF2 Nef proteins reflects their membrane
binding properties, membrane fractionation experiments were
performed with infected Jurkat cells (Fig. 4C). Segregation of
transferrin receptor (TfR) and 14-3-3 into the pellet (P) and
cytosolic (S) cell fractions, respectively, served as quality
control of the fractionation procedure. Expectedly, significant
amounts of both Nef proteins (approximately 35%) were
detected in the P fraction that contains membranes,
cytoskeleton and protein aggregates. In contrast, the non-
myristoylated variants of NL4-3 and SF2 Nef predominantly
partitioned in the S fraction (approximately 94%). Together,
these results identify previously unrecognized determinants
for virion incorporation of SF2Nef, reveal that myristoylation
is not a strict requirement for this process and demonstrate
similar contribution of myristoylation to membrane binding of
SF2 and NL4-3 Nef proteins.Characterization of the determinants that mediate
enhancement of virion infectivity by SF2Nef
To investigate the efficiencies by which the Nef variants
represented in the virus panel augment HIV-1 infectivity in a
single round of replication, TZM indicator cells were infected
with 0.5 ng CA of the 293T derived virus stocks analyzed for
virion incorporation in Figs. 3A and B. 36 h post-infection,
HIV-infected cells were quantified on the basis of their
characteristic blue staining (Figs. 5A and B). As expected,
Δnef virions were approximately 4-fold less infectious that
HIV-1 WT particles (Aiken and Trono, 1995; Miller et al.,
1994; Schwartz et al., 1995; Spina et al., 1994). Based on this
result, virus particles with less than 30% infectivity relative to
WT HIV-1 were considered deficient in Nef induced
enhancement of infectivity. Such complete lack of Nef activity
(−) was only observed for the Δ12–39 and the Δ59–61
variants. The R4A4 and E181Q mutations had no effect and
resulted in virions with relative infectivities greater than 70%
of wt HIV-1 and were thus considered as fully active (++). All
other mutations caused intermediate phenotypes with partial
Nef activity resulting in virions with relative infectivities
ranging between 30% and 70% (+). Interestingly, the relative
infectivity of G2A viruses ranged between 37 and 64% of that
of WT and thus always scored intermediate in the infectivity
assay. Furthermore, also the infectivity of HIV-1 particles
produced from PM1 T lymphocytes was significantly
increased by the G2A and E4A4 Nef but not by the Δ12–
39 variant (Fig. 5C). Thus, several distinct interaction surfaces
are required for Nef-mediated enhancement of virion infec-
tivity and non-myristoylated Nef retains considerable activity
in this assay.
Fig. 4. Analysis of HIV particle preparations. (A) Comparison of virion incorporation of Nef proteins from the HIV-1 strains NL4-3 and SF2. 293T cells were
transfected with HIV-1 NL4-3 proviral DNA encoding for NL4-3 or SF2 Nef proteins or their non-myristoylated G2A variants. Virion pellets and cell lysates were
analyzed for the presence of CA and Nef by Western blotting. (B) 293T cells were transfected with proviral DNA or an expression plasmid for the SF2Nef.GFP fusion
protein. Virion pellets and cell lysates were analyzed for the presence of CA (left panel) and Nef.GFP (right panel) by Western blotting. The asterisk denotes a non-
specific band detected by the anti-GFP antibody in virus pellets. (C) Membrane fractionation of infected Jurkat T lymphocytes. Three days post-infection with viruses
expressing the indicated Nef proteins, postnuclear extracts of Jurkat cells were fractionated into soluble (S) and pellet (P) fractions and analyzed byWestern blotting for
the distribution of Nef. Transferrin receptor (TfR) and 14-3-3 proteins were analyzed as markers for S and P fractions, respectively.
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lymphocytes
We next investigated steady state cell surface levels of CD4
in Jurkat T cells infected with the nef virus panel (Fig. 6). To
define the experimental setup, cells were infected with WT and
Δnef viruses and stained for CD4 and intracellular CA 18
(early) and 48 (late) h post-infection (Fig. 6A). At the early time
point, CD4 cell surface levels were not markedly reduced in
Δnef infected cells relative to the mock infected control. In
contrast, WT-infected cells displayed a significant reduction in
cell surface CD4, reflecting the action of Nef. Of note, analysis
of the same cells at later time points revealed efficient CD4
downregulation in cells infected by both WT and Δnef viruses,presumably reflecting the activity of Vpu and Env (Chen et al.,
1996). Thus, Nef-specific effects of the virus panel were
determined at 18 h post-infection (Fig. 6B). Quantification of
CD4 cell surface levels relative to the mock infected control
cells (100%) revealed that Δnef infected cells maintained more
than 75% of cell surface CD4, while these levels were reduced
to less than 20% in WT-infected cells. Nef variants removing
cell surface CD4 down to at least 30% were considered
comparable to WT (++), an activity resulting in 30–70% cell
surface presentation was scored as intermediate (+), and Nef
variants that did not reduce cell surface CD4 below 70% were
considered as inactive in this assay (−). As expected, the Nef
variants thought to be unable to interact with the endocytic
machinery (LLAA, EDAA) or with CD4 (Δ59–61) failed to
Fig. 5. Enhancement of virion infectivity by Nef variants. Single round of replication analysis on TZM cells. TZM cells were infected with 0.5 ng CA of the identical
virus stocks that were analyzed for Nef virion incorporation in Fig. 3. 36 h post-infection, the cells were fixed, stained for β-galactosidase, and the number of blue cells
was counted. Data represent average values from two independent experiments with triplicate measurements each with the indicated standard error of the mean.
Depicted is the relative virion infectivity (number of blue cells per ng CA) with values for HIV-1NL4-3 NefSF2 (wt) arbitrarily set to 100% (A) or absolute numbers of
infected cells per ng p24 (B, C). (A, B) 293T cell derived virus. Relative activity in enhancement of virion infectivity was grouped as “no Nef activity, (−) for values
within 1 SD of Δnef (up to 30% activity), “intermediate Nef activity” (+) between 30–70% activity and “full Nef activity” (++) between 70–100% activity. (C) Virus
derived from infection of PM1 T lymphocytes.
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to A only partially affected Nef's ability to reduce cell surface
CD4 levels, suggesting that this mutation is insufficient to
disrupt the Nef–CD4 interaction. Interestingly, loss of CD4
downmodulation was also observed for the Δ12–39 variant.
Three variants (G2A, L116A and RRLL) showed intermediate
CD4 downregulation activity, while all other Nef variants
efficiently removed the HIV entry receptor from the surface of
virally infected cells.
Analysis of Nef-mediated MHC-I downregulation from the
surface of HIV-infected T lymphocytes
With the same experimental setting effects of Nef on MHC-I
surface presentation were monitored (Fig. 7). In this case, no
significant difference was observed between early and late time
points: at both times, downmodulation of MHC-I was readily
observed in WT but not in Δnef infected cells (Fig. 7A). Thus,
under these experimental conditions, Nef is the only HIV gene
product with significant effects on MHC-I cell surface levels.
Reflecting the relatively less efficient downregulation of MHC-I
by Nef as compared to CD4, MHC-I cell surface levels were
only reduced to 58% in WT-infected cells relative to mock
infected controls. Infection with the Δnef control did not affect
MHC-I cell surface levels. Of all Nef variants analyzed, only
G2A, E4A4 and RRLL failed to downregulate MHC-I (relativelevels higher than 80%), and only theΔ12–39 variant displayed
an intermediate phenotype (58–80%). The majority of the tested
Nef proteins efficiently downmodulated cell surface MHC-I.
Interestingly, the LLAA, EDAA and Δ59–61 mutants, which
no longer downregulated CD4, were more efficient than the
WTNef protein in MHC-I downmodulation. It is likely that, in
the absence of interaction of Nef with sorting proteins involved
in CD4 trafficking or CD4 itself, the viral protein is more
“available” for trapping MHC-I molecules. It was also
surprising that the AxxA variant of Nef that was reported to
be deficient in MHC-I downmodulation because of its inability
to interact with SH3 domains (Greenberg et al., 1998a, 1998b;
Manninen et al., 1998) retained actually a good activity on
MHC-I. To exclude that the use of a pan anti-MHC-I antibody
and the staining procedure for intracellular p24 affected the
outcome of these experiments, we analyzed the effects of Nef in
T1 lymphoid cells, which express the Nef-sensitive HLA-A2
molecule. Moreover, these cells express GFP under the control
of the HIV-1 LTR indicating productive HIV infection by GFP
fluorescence without the need for additional staining proce-
dures. When analyzed 5 days post-infection, cell surface HLA-
A2 was downmodulated to approximately 40% in cells infected
with WT but not with Δnef virus (Fig. 8). As observed in Jurkat
cells, most of the Nef variants including the AxxA mutant
displayed activities comparable to WTNef and the RRLL
variant was fully defective in HLA-A2 downmodulation. The
Fig. 6. CD4 surface levels in Jurkat cells infected with HIV-1 expressing various Nef mutants. (A) CD4 and CA expression in Jurkat cells infected with WT (NL4-3
SF2Nef) or ΔNef HIV (NL4-3 ΔNef). Jurkat cells were infected with viruses expressing the indicated Nef mutants. At 18 h (“early” panels) and 48 h (“late” panels)
post-infection, cells were stained with anti-CD4 (surface staining) and anti-CA (intracellular staining) antibodies. (B) Activity of the various Nef mutants. CD4 surface
levels of uninfected cells were set to 100%. CD4 surface expression with the panel of HIV-1 variants was determined 18 h after infection, within the fraction of CA+
cells. Data are mean ± SD of 3 independent experiments.
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to approximately 60% of the control and thus displayed
intermediate activity. Importantly, the E4A4 Nef protein that
did not affect MHC-I surface levels in Jurkat cells was fully
active in downmodulating HLA-A2 in T1 cells. Together, these
results emphasize the need for the characterization of molecular
determinants for Nef activity in cells acutely infected with HIV
and pinpoint to potential cell type specific differences in the
mechanism employed by Nef for cell surface receptor
downmodulation.
Analysis of the determinants in Nef for the optimization of
HIV-1 replication in primary human peripheral blood
lymphocytes
As the final functional correlate we assayed the virus panel
for replication in human peripheral blood lymphocytes (PBL)
that had not been stimulated prior to infection. Following
established procedures to reveal positive effects of HIV-1 Nef
on viral spread (Miller et al., 1994; Spina et al., 1994; Welker
et al., 1996), isolated PBMC were infected, cultured for 3 days
and subsequently activated by PHA/IL-2. After 3 days of
stimulation, PBL were cultured in the presence of IL-2, and
virus replication was monitored by quantification of CA
antigen in the cell culture supernatant. We first tested the
replication kinetics of HIV-1 WT and Δnef on PBL from
various independent donors. As shown in Figs. 9A and B, PBL
from most donors displayed a delayed replication curve forΔnef relative to the WT control. In the experiments shown, a
virus inoculum of 1 ng CA was used. Using higher doses of
virus input accelerated virus spread, often masking the
influence of Nef on HIV-1 replication (data not shown).
Furthermore, some individual donors did not reveal significant
differences between replication of WT and Δnef HIV-1 even
with low doses of virus input (data not shown). The PBL from
the donor shown in Fig. 9B were used to assay virus replication
for the entire virus panel in parallel. Fig. 9C presents CA
concentrations in the medium at days 2 and 4 post-activation
(black and grey bars, respectively). Shown is one experiment
representative of three independent experiments each carried
out in quadruplicates. Presumably due to the low virus input
needed to reveal a Nef phenotype, individual wells did not
produce detectable amounts of virus over the course of the
experiment. These wells were excluded from the analysis, and
the total number of productively infected wells is provided in
Fig. 9C. Based on the CA production of wt and Δnef viruses
on day4, the panel was grouped as having full (++, 100–70%),
intermediate (+, 70–30%) and no (−, below 30%) Nef activity.
Variants such as E4A4 that could not be attributed with
certainty to a specific activity group due to variability between
experiments were scored as intermediate between the respec-
tive activity groups (see Table 2). Comparable overall grouping
was obtained with PBL from an independent donor (data not
shown). Based on this analysis, G2A, LLAA, EDAA and
Δ12–39 Nef variants were identified as defective in boosting
HIV-1 replication in primary T cells. This effect was most
Fig. 7. MHC-I surface levels in Jurkat cells infected with HIV-1 expressing various Nef mutants. (A) MHC-I and CA expression in Jurkat cells infected withWT (NL4-
3 SF2Nef) orΔNef HIV (NL4-3ΔNef ). Jurkat cells were infected with viruses expressing the indicated Nef mutants. At 18 h (“early” panels) and 48 h (“late” panels)
post-infection, cells were stained with anti-MHC-I (surface staining) anti-CA (intracellular staining) antibodies. (B) Activity of the various Nef mutants. MHC-I
surface levels of uninfected cells were set to 100%. MHC-I surface expression with the panel of HIV-1 variants was determined 18 h after infection, within the fraction
of CA+ cells. Data are mean ± SD of 3 independent experiments.
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replicated even less efficiently than Δnef. Re-examination on
PBL from a different donor consistently revealed replicationFig. 8. MHC-I A2 surface levels in CEM cells infected with HIV-1 expressing vario
(NL4-3 SF2Nef) or ΔNef HIV (NL4-3 ΔNef). CEM cells were infected with viruses
levels and LTR driven GFP expression were analyzed by flow cytometry. (B) Activity
to 100%. HLA-A2 surface expression with the panel of HIV-1 variants was determine
2 independent experiments.comparable to HIV-1Δnef (data not shown). In contrast,
mutation of R4, W61, E4, V78 and L116 did not have
significant impact on Nef's ability to enhance viral spread inus Nef mutants. (A) MHC-I and CA expression in CEM cells infected with WT
expressing the indicated Nef mutants. At 5 days post-infection HLA-A2 surface
of the various Nef mutants. HLA-A2 surface levels of uninfected cells were set
d 5 days post-infection, within the fraction of GFP+ cells. Data are mean ± SD of
Fig. 9. Effects of Nef variants on HIV-1 replication in PBL. HIV replication was measured in 96-well plates on 1 × 105 PBL per well and 1 ng CAvirus input. Freshly
isolated, non-activated cells were infected (day −6) for 3 days and subsequently activated by PHA/IL-2 for 3 days. Starting from day 0, cells were kept in the presence
of IL-2, and cell culture supernatants were collected each day to monitor CA production. (A, B) Representative replication kinetics of wt (diamonds) and Δnef
(squares) HIV-1 on PBL from two different donors. CAvalues represent the average from quadruplicate infections performed in parallel. (C) Relative CA production of
the isogenic nef virus panel on day 2 (black bars) and on day 4 (grey bars). CA values for wt were arbitrarily set to 100%. Shown is relative CA production form
individual infections representative of the average result obtained in three independent experiments performed in quadruplicates. Relative CA production on day 4 was
used to group Nef variants as “no Nef activity (−, up to 30% relative activity, white bars), “intermediate Nef activity” (+, 30–70% relative activity) and “full Nef
activity” (++, 70–100% relative activity). Numbers below the bars indicate how many of all individual values tested resulted in the grouping represented here.
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activity. As Nef has also been reported to increase the TCID50
determined on activated PBMC four donor pools (Miller et al.,
1994; Sinclair et al., 1997), TCID50 values were also
determined for our virus stocks. While this analysis confirmed
an increase of HIV-1 infectivity on human primary T
lymphocytes, results from independent experiments gave
heterogeneous results and did not allow a firm quantification
of the contribution of individual Nef protein interaction sites tovirus replication (data not shown). Together, distinct protein
interaction sites in Nef were identified that are required for
optimal replication of HIV-1 in primary human T cells.
Discussion
This study presents the functional characterization of the
HIV pathogenicity factor Nef in HIV-infected cells using a
broad panel of defined Nef mutants in an isogenic background.
Table 2
Summary of relative Nef activities in HIV-1 infected cells
Nef variant Loss of interaction with CD4 downregulation MHC-I a downregulation Infectivity enhancement Virion incorporation PBL replication
WT − ++ ++/++ ++ ++ ++
G2A NMT + −/+ + ++ −
R4A4 membranes? ++ ++/++ ++ ++ +/++
W61A CD4 + ++/++ + ++ +/++
E4A4 PACS ++ −/++ + − +/++
AxxA SH3 domains ++ ++/++ + ++ +
V78A Pak2, SH3 dom. ++ ++/++ + ++ ++
R81A Pak2, SH3 dom. ++ ++/++ + ++ +/++
L116A Pak2, Nef + ++/++ + + ++
LLAA AP-1,-2, -3, V1H − ++/++ + ++ −
EDAA AP-2, V1H − ++/++ + ++ −
E181Q C-Raf ++ ++/++ ++ ++ +
P73A TCR zeta, Pak2 ++ ++/++ + ++ +/++
Δ12–39 NAKC − +/+ − − −
Δ59–61 CD4 − ++/++ − ++ +
RRLL Pak2, Nef + −/− + ++ +
Δnef all − −/− − − −
a MHC-I in Jurkat/HLA-A2 in T1.
333O.T. Fackler et al. / Virology 351 (2006) 322–339All Nef variants included in this study expressed proteins of the
expected size but to somewhat variable levels. These variations
were cell type dependent: while several Nef variants were less
stable than wt in 293T cells, almost all Nef variants expressed to
higher levels than wt in T lymphocytes. Moreover, Nef variants
such as W61A, Δ59–61 or E4A4 that were expressed to lower
levels in 293T cells still displayed full biological activity in
select Nef functional assays, indicating that the observed
variations in expression levels are unlikely to account for most
of the functional differences observed between individual Nef
variants. The analysis of Nef's subcellular localization and its
effect on the cell surface density of CD4 and MHC-I molecules
served as basic functional characterization of the Nef virus
panel. These investigations did not include the analysis of signal
transduction properties of Nef that can be monitored, e.g., by its
ability to associate with and activate the cellular Pak and Lck
kinases (Baur et al., 1997; Fackler et al., 2000; Renkema et al.,
1999; Witte et al., 2004). Such studies depend on prior
immunoisolation of Nef. Since the aim of this study was the
characterization of Nef in its natural proviral context, no epitope
tags were added to the Nef proteins in order to prevent all
putative modulation of Nef's biological activity. Due to the lack
of specific antibodies that immunoisolate all Nef variants tested
here with comparable efficiency without interfering with its
kinase association, the analysis of these signaling events was
precluded. The analysis of CD4 surface levels in infected cells
gave results that are consistent with the prevailing idea that Nef
targets the cytoplasmic tail of CD4 with its hydrophobic pocket
and routes the receptor to degradation via interactions with the
cellular endocytosis machinery that are mediated by its c-
terminal flexible loop (Lama, 2003). The results obtained also
confirm the mechanistic segregation of CD4 and MHC-I
downmodulation in HIV-infected cells.
Conversely, our analysis of Nef-mediated downregulation of
MHC-I in the context of HIV-1 infection yielded several
noteworthy insights. First, Nef was confirmed as the only HIV
gene product with an appreciable effect on MHC-I cell surfaceexposure. Second, Nef reduced overall MHC-I or HLA-A2 cell
surface density to only 40% in infected T lymphocytes in this
study. Of note, similarly moderate levels of MHC-I down-
modulation can be sufficient to protect HIV-infected cells from
CTL lysis (Tomiyama et al., 2005). Third, the mapping of Nef
determinants in the infection context varied from previous
results using Nef overexpression systems. Surprisingly, disrup-
tion of the PxxP motif in Nef had no appreciable effect on
MHC-I downregulation, indicating that the proposed role for
the interaction of Nef with SH3 domains in this process
(Blagoveshchenskaya et al., 2002; Greenberg et al., 1998a,
1998b) may not be relevant in HIV-infected T lymphocytes.
This is consistent with recent results showing that the proline at
position 78 rather than the two central prolines of the SH3
binding motif in Nef are critical for Nef-mediated MHC-I
downregulation (Yamada et al., 2003), and that this Nef activity
is indeed uncoupled from its ability to bind SH3 domains (N.
Casartelli and M. Doria, personal communication). On the other
hand, residues 12–39, Nef myristoylation and the di-arginine
motif were essential for full Nef activity on MHC-I.
Interestingly, an N-terminal amphipatic helix missing in the
Δ12–39 Nef mutant was recently shown to assemble a complex
containing MHC-I and AP-1 that is critical for Nef's down-
modulating ability (Roeth et al., 2004; Williams et al., 2005).
The requirement for myristoylation likely mirrors the need for
efficient membrane attachment of Nef for receptor down-
modulation. The RRLL Nef mutant classically served as a loss-
of-function variant for the association of Nef with Pak activity
(Sawai et al., 1996). Since Nef mutants such as AxxA that also
do not associate with active Pak2 (Fackler et al., 1999;
Manninen et al., 1998) downregulated MHC-I with full
efficiency, involvement of Pak association can be excluded.
Of note, the RRLL Nef variant did not reach full activity in any
of the assays performed here except virion incorporation. This
may reflect either broad unspecific effects, the slightly reduced
stability of this protein or specific interference with Nef
multimerization caused by the RRLL mutation (Liu et al.,
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Nef with PACS was required for MHC-I downmodulation in
Jurkat but not in T1 cells. This emphasizes the possibility that
Nef employs diverse molecular mechanisms for downregulation
of MHC-I depending on the cellular context (Kasper and
Collins, 2003).
One surprising result of our analysis was the fact that
myristoylation was not absolutely required for most activities of
SF2Nef and in particular not for its incorporation into HIV-1
virions. Such residual activity of non-myristoylated Nef likely
reflects its relatively high levels of expression, and the fact that
myristoylation is not the only determinant for membrane
anchorage of Nef (Bentham et al., 2006). In contrast, virion
incorporation of Nef from HIV-1 NL4-3 and HxB2 was reported
to strictly require myristoylation (Bukovsky et al., 1997; Chen
et al., 1998; Welker et al., 1998). Our results suggest that this
discrepancy reflects allelic differences between Nef proteins
from the HIV-1 strains NL4-3 and SF2 that is however, not
determined by differential contributions of the myristoyl moiety
to overall membrane binding. Consistent with such allelic
differences, a mutation in the N-terminal basic cluster of Nef
(R4A4), that was previously identified as one determinant for
membrane binding of NL4-3Nef (Welker et al., 1998), does not
impact on the activity of SF2Nef in HIV-1 infected cells (this
study) or its membrane association (S.I. Giese and O.T. Fackler,
unpublished). While the reason for this differential behavior
remains to be determined, it may also account for the
differential activity during HIV-1 entry in some cell systems
(Fackler and Peterlin, 2000). In contrast to myristoylation, the
amphipatic N-terminal helix that serves for the assembly of the
NAKC signalosome and the association of Nef with the AP-1/
MHC-I complex (Baur et al., 1997; Roeth et al., 2004; Williams
et al., 2005) as well as the stretch of acidic amino acids
mediating Nef's interaction with PACS (Piguet et al., 2000)
were identified as novel determinants for virion incorporation of
Nef. The molecular basis for the requirement of these motifs is
uncertain. One possible model of virion incorporation of Nef
predicts this to be a consequence of its association with the
plasma membrane at budding sites. The rough correlation
between determinants for Nef virion incorporation and its
ability to downregulate cell surface MHC-I observed could
indicate that Nef utilizes a common pathway for retention of
MHC-I molecules during biosynthetic transport and its own
translocation to budding virions. However, the Nef mutants
lacking virion incorporation were fully functional in assays such
as CD4 downmodulation that strictly depend on membrane
association of Nef and did not display significant changes in
their subcellular localization. An alternative view holds that Nef
is incorporated into HIV particles by virtue of its physical
interaction with GagPol (Costa et al., 2004). The motifs in the
N-terminus of Nef may therefore be involved in the interaction
of Nef with HIV structural proteins. Additionally, the analysis
of this virus panel allowed us to draw conclusions on the role of
virion Nef in the context of HIV replication. Several variants of
the panel were efficiently incorporated into HIV particles yet
failed to support virus replication in PBL, and the E4A4 Nef
variant optimized HIV spread despite the lack of detectablevirion incorporation. Similarly, no strict correlation was
observed between the amounts of virion incorporated Nef and
its ability to augment the infectivity of HIV-1 particles. This is
seemingly at odds with recent reports from intravirion fusion
and natural endogenous reverse transcription experiments,
suggesting that virion Nef may be instrumental for Nef-
mediated enhancement of virion infectivity and that localize the
effect of Nef to a post-entry step in HIV target cells (Aiken and
Trono, 1995; Cavrois et al., 2004; Khan et al., 2001, 2005;
Schwartz et al., 1995; Tobiume et al., 2003; Zhou and Aiken,
2001). However, the results of these studies could also be
explained by modifications of virion components imprinted by
Nef during virus particle production. Together, our results
strongly argue against an essential role of virion Nef in the
replication of HIV-1 in PHA-activated PBL and in Nef-
mediated enhancement of virion infectivity.
Our results also reveal a requirement for an N-terminal
amphipatic helix for Nef-mediated CD4 downregulation and
enhancement of virion infectivity as well as for Nef's virion
incorporation. The interpretation of this result is complicated by
the apparently reduced stability of the NefΔ12–39 variant in
some cells. However, in the context of T lymphocyte infection,
NefΔ12–39 was well expressed and retained partial MHC-I
downregulation activity, a Nef function that requires high Nef
expression levels (Liu et al., 2001). In contrast, this Nef variant
failed to downmodulate cell surface CD4, which can readily be
induced by low levels of functional Nef, suggesting that the
defects observed reflect at least in parts specific alterations of
Nef activity introduced by the 12–39 deletion. Such a role
would be consistent with one report on the role of amino acid
positions 29 and 36 in Nef from HIV-1 NA7 in Nef-mediated
CD4 downregulation (Iafrate et al., 1997), while deletion of this
helix had no effects in other studies using Nef overexpression
(Mangasarian et al., 1999; Williams et al., 2005). Mechanisti-
cally, this helix serves as interaction site of the NAKC
signalosome as well as a protein complex containing AP-1
and MHC-I and was previously reported to contribute to the
positive effects of Nef on HIV-1 replication in Jurkat cells (Baur
et al., 1997; Roeth et al., 2004; Williams et al., 2005). The data
presented here confirm and extend these results to primary
human T cells. In line with these findings, this domain was
recently reported to contribute to the pathogenic potential of Nef
in transgenic mice (Hanna et al., 2004). Whether these
functional consequences of deletions in the N-terminus of Nef
reflect the direct involvement of NAKC-mediated signaling,
AP-1-mediated intracellular protein transport or other effects of
this protein interaction surface warrants further investigation.
One important aspect of this study lies in the evaluation of
HIV-1 replication in PBL stimulated with PHA post-infection as
read-out for positive effects of Nef on viral spread. It has been
described more than a decade ago that Nef provides detectable
advantage to HIV replication in primary human T cells only
when they are activated following infection but not when
previously activated cells are used (Miller et al., 1994). This
experimental set-up, that was also employed here, was
subsequently used as correlate for Nef activity by many
investigators (e.g., Rucker et al., 2004; Spina et al., 1994;
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observation of Nef-mediated enhancement of HIV-1 replication
in that system. However, the accurate quantification of activities
of a large virus panel proved difficult in our hands. Since low
doses of virus input have to be used to reveal any effect of Nef,
infections are carried out near the threshold for a productive
infection, resulting in individual infections that remain non-
productive. Furthermore, the variability in CA production
between individual parallel infections together with the
relatively subtle overall effect of Nef in this system did not
allow solid quantification of intermediate Nef activities. Thus,
while this experimental set-up serves well to detect loss-of-
function mutations in Nef, it does not seem suitable for the
quantification of partial Nef activities. Within these limitations,
the rough grouping implemented here revealed that all Nef
variants without detectable activity in boosting HIV-1 spread
were defective in the downregulation of cell surface CD4.
Similarly, all Nef variants without CD4 downregulation activity
failed to enhance HIV-1 replication in PBL, with the exception
of NefΔ59–61 that retained weak activity. No close correlation
could be established for optimal HIV replication in PBL and the
other Nef activities tested, indicating that these Nef effects may
not be directly involved in HIV-1 replication in this experi-
mental system. These results confirm and extend the previous
notion that downmodulation of CD4 by Nef contributes to its
effects on HIV replication (Glushakova et al., 2001; Lundquist
et al., 2002). This may reflect the role of Nef-mediated CD4
downregulation in interference with negative effects of CD4 on
HIV-1 infectivity and particle release as well as superinfection
of already productively infected cells (Benson et al., 1993;
Lama et al., 1999; Michel et al., 2005; Ross et al., 1999) but also
other, CD4-independent effects mediated by the same protein
interaction surfaces in Nef (Madrid et al., 2005). While these
results are consistent with a requirement for Nef-mediated CD4
downmodulation for optimal viral replication, the intermediate
activities of Nef variants with full CD4 downregulation capacity
(AxxA, E181Q, RRLL) clearly indicate the existence of other
mechanisms utilized by Nef to facilitate HIV-1 spread in
primary human T cells. Interestingly, infection of PBL from
some donors did not reveal any Nef phenotype (not shown).
Revealing the cause for this donor variability would provide
valuable information on these additional mechanisms. Of note,
alternative primary cell systems have been reported recently that
reveal more pronounced effects of Nef on HIV replication.
These include cocultures of T cells with immature dendritic
(Fackler et al., 2001; Petit et al., 2001) or vascular endothelial
cells (Choi et al., 2005), ex vivo cultures of human tonsils
(Glushakova et al., 2001) and T cells activated by SEB and
mitomycin C-killed DCs (Lundquist et al., 2002). Thus, the
nature of the activation stimulus appears to determine to which
degree Nef is required for optimal HIV replication in primary
human T cells. However, it is unclear at this point if all these
systems monitor similar aspects of Nef biology and how
accurately they reflect Nef's enhancement of virus replication in
vivo. This question warrants further in depth analysis of the
molecular mechanisms employed by Nef to augment HIV
replication in such primary cell systems. The virus panel ofisogenic Nef variants presented in this report will be a valuable
tool for these analyses.
Materials and methods
Cells and reagents
293T and TZM (JC53BL) cells were maintained in DMEM
high medium supplemented with 10% fetal calf serum, L-
glutamine and antibiotics. Jurkat, PM1, C8166, MT4 and T1
(CEMx721.174 cells carrying an HIV-LTR-GFP cassette and
expressing HLA-A2) lymphoid cells were cultured in RPMI
1640 medium supplemented accordingly. RPMI for PBMC
cultures was supplemented with 10% FCS, 0.1% Glutamax
(Invitrogen, Karlsruhe, Germany), 0,1% 1 M HEPES pH 7,4
and antibiotics.
Expression plasmids
Expression plasmids for GFP fusion proteins of HIV-1 SF2
Nef and its mutants were described previously (Keppler et al.,
2005). Isogenic proviral constructs expressing various nef genes
were constructed based on the pNLblue vector that contains the
full-length proviral DNA of HIV-1 NL4-3 in the blueskript 2.9
vector backbone without flanking cellular genomic DNA. A
single NotI restriction site was eliminated by digest, fill-in and
religation to create pNLblueΔMCSNot. From this construct, a
StuI/XhoI fragment was excised and replaced with the
corresponding fragment from the pNL4-3Δmyr proviral clone
(Welker et al., 1998), that carries a NcoI restriction site at the 5′
end of nef, resulting in the construct pNLblue Nco nef. Using
mutagenic PCR, a NotI restriction site was introduced at the 3′
end of nef to create the pNLblue Nco nef Not vector. All nef
variants from HIV-1SF2 described in this study were PCR
amplified from DNA templates provided by the consortium
“The HIV-1 pathogenicity factor Nef as a novel therapeutic
target” (project QLK2-CT-2000-01630 in the fifth EC Frame-
work Programme) or described previously (Keppler et al., 2005;
Krautkramer et al., 2004) with primers introducing NcoI and
NotI sites 5′ and 3′ of the nef amplicon, respectively, and were
subcloned in the NcoI/NotI digested pNLblue Nco nef Not
vector. The complete nucleotide sequence of all nef inserts of
these proviral clones as well as of PCR amplicons from cells
infected with the respective virus stocks was verified by
sequencing of both DNA strands.
Western blotting
For Western blot analysis, samples were boiled in SDS
sample buffer, separated by 10% SDS-PAGE and transferred to
a nitrocellulose membrane. Protein detection was performed
following incubation with appropriate first and secondary
antibodies using the super signal pico detection kit (Pierce,
Bonn, Germany) according to the manufacturer's instructions.
CA and Nef were detected using the polyclonal rabbit serum
CA1 (Muller et al., 2004) and the polyclonal sheep serum
Arp444 (Coates et al., 1997), respectively. For quantification of
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fluorophor Alexa 680 (Invitrogen) were used to detect and
quantify the signals using a Odyssey imaging system (LI-COR
Biosciences, Bad Homburg, Germany).
Virus stocks and virion infectivity
Virus stocks were generated by transfection of proviral HIV
plasmids into 293T cells by the Ca-phosphate method. Two
days after transfection, culture supernatants were harvested.
The CA concentration of concentrated stocks was determined
by CA antigen enzyme-linked immunosorbent assay (ELISA)
as described (Muller et al., 2000). The relative infectivity of
HIV-1 particles was determined by CA ELISA and a
standardized 96-well TZM blue cell assay as described
(Keppler et al., 2005). Briefly, infections were carried out in
triplicates with 0.5 ng CA input virus. 36 h post-infection,
cells were fixed, stained for β-galactosidase, and the number
of blue cells was determined by microscopy. For virus
production from PM1 T lymphocytes, 1 × 106 cells were
infected with 3 × 105 infectious units (determined on TZM
cells), and culture supernatants were harvested 3 days post-
infection. For the infection of MT4 T lymphocytes, infected
C8166 cells displaying pronounced syncytia were cocultured
with MT4 cells, and cells were harvested after multiple serial
passages.
Subcellular fractionation
Subcellular fractionation was performed using slight
modifications of a previously described protocol (Alland et
al., 1994). In brief, 1 × 107 Jurkat cells were infected with
600 ng of the indicated HIV-1 virus stocks by virus by spin
infection at 20×g for 1.5 h. 3 days post-infection, the cells
were resuspended in hypotonic buffer (10 mM Tris, pH 7.4,
0.2 mM MgCl2, protease inhibitor cocktail) and homogenized
with 50 pipetting steps. Postnuclear supernatants were adjusted
to 0.25 M sucrose and 1 mM EDTA and centrifuged at
100,000×g for 50 min. Volumes of pellets (P100) and
supernatants (S100) were equalized using RIPA buffer
(150 mM NaCl, 50 mM Tris–HCl, pH 7.2, 1% Triton-X
100, 0.1% SDS). 6× Sample buffer was added, and aliquots
were analyzed by Western blotting using antibodies against
Nef, TfR (mAb H68.4, Zymed Laboratories Inc., South San
Francisco, CA) and 14-3-3 γ (C-16, Santa Cruz Biotechnol-
ogy, Heidelberg, Germany).
Virion incorporation
For the analysis of virion incorporation of Nef, 400 μl of
cell culture supernatants containing infectious virions was
placed on top of 80 μl 20% sucrose solution. After
ultracentrifugation (TLA45 rotor, 44,000 rpm, 4 °C,
60 min), the pellets were resuspended in 6× sample buffer.
Volumes corresponding to 100 or 5 ng CA were then
analyzed by Western Blotting with antibodies against Nef and
CA, respectively.Flow cytometry
1 × 106 Jurkat T cells were infected in culture medium
containing HEPES (pH7.4, 20 mM) and DEAE-dextran (20 μg/
ml) with HIV-1 expressing Nef variants at a concentration of
50 ng of CA/ml for 2 h at 37 °C. Cells were washed and seeded
in 24-well plates. Jurkat cells were harvested 18 h and 48 h
post-infection and stained with anti-CA (KC57-PE, Coulter,
Miami, FL) antibody in combination with either anti-MHC-I
(W6/32-FITC, Sigma-Aldricht, St Louis, MO), or anti-CD4
(CD4-APC, Immunotech-Coulter, Marseilles, France) antibo-
dies. Briefly, cell surface molecules (MHC-I, CD4) were
stained at 4 °C for 30 min prior to fixation (4% PFA for 10 min
at 25 °C) and permeabilization (PBS containing 1% BSA and
0.05% saponine for 15 min at 25 °C). Intracellular staining
(anti-Gag) was then performed in permeabilization medium for
45 min at 25 °C. T1 cells were fixed and stained with the HLA-
A2 specific antibody BB7.2 (BD Biosciences) without prior
permeabilization 5 days post-infection. Samples were analyzed
by flow cytometry using a FACSCalibur cytometer (Becton
Dickinson, San Jose, CA).
Immunofluorescence
To visualize the subcellular localization of Nef, TZM cells
were seeded onto glass coverslips and infected with virus
corresponding to 2 ng CA or transfected with 1 μg of proviral
DNA or Nef.GFP expression plasmid. 36 h later, the cells were
fixed with 3% paraformaldehyde/phosphate-buffered saline
(10 min at room temperature), permeabilized with 0.1% Tx-
100 and stained with antibodies against CA (CA1) and Nef
(mAb #158 (Fackler et al., 1997)) followed by appropriate
fluorescent secondary antibodies. Following extensive washing,
cells were mounted with Histoprime (Histogel, Linaris,
Germany). Fluorescence microscopy images were acquired
with an Olympus IX70 microscope with a 60× oil immersion
objective equipped with a CCD camera and processed with
analySIS 3.0 software (Soft Imaging System, Münster,
Germany). Final images were processed in Photoshop 6.0
(Adobe Systems, Mountain View, CA).
Replication in primary human peripheral blood lymphocytes
(PBL)
To analyze the effects of Nef on HIV replication in primary
human T lymphocytes, peripheral blood mononuclear cells
were isolated from healthy donors by Ficoll gradients using
Ficoll-Paque Plus (Amersham Biosciences, Uppsala, Sweden).
For infection, cells were thawed and kept in bulk cultures in
RPMI, 10% FCS at 1 × 106 cells/ml overnight. 1 × 105 cells/
well were then seeded in V-bottom 96-well plates and infected
with 1 ng CAvirus input per well the following day. 3 days later,
the cells were washed and stimulated with 2 μg/ml PHA
(Sigma) and 20 nM IL-2 (Chiron, Emeryville, CA) for 3 days.
After stimulation, the PBL were washed and resuspended in
200 μl RPMI containing FCS and IL-2. Each day, 100 μl cell
culture supernatant was replaced with fresh medium, and the
337O.T. Fackler et al. / Virology 351 (2006) 322–339amounts of CA in the cell culture supernatant were quantified to
monitor virus replication.
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